Revolution Medicines Inc
1RVMD
Company Profile
Business description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.
Contact
700 Saginaw Drive
Redwood CityCA94063
USAT: +1 650 481-6801
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
700
Stocks News & Analysis
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
stocks
ASX results reaction: WiseTech, Woolies, Sigma and more
A round up of notable stories and reactions as ASX reporting season rolls on.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.80 | 20.60 | -0.22% |
| CAC 40 | 7,706.18 | 2.28 | 0.03% |
| DAX 40 | 23,975.65 | 73.44 | 0.31% |
| Dow JONES (US) | 45,544.88 | 92.02 | -0.20% |
| FTSE 100 | 9,198.61 | 11.27 | 0.12% |
| HKSE | 25,617.42 | 539.80 | 2.15% |
| NASDAQ | 21,455.55 | 249.61 | -1.15% |
| Nikkei 225 | 42,188.79 | 529.68 | -1.24% |
| NZX 50 Index | 13,070.45 | 139.72 | 1.08% |
| S&P 500 | 6,460.26 | 41.60 | -0.64% |
| S&P/ASX 200 | 8,927.70 | 21.10 | -0.24% |
| SSE Composite Index | 3,875.53 | 17.60 | 0.46% |